证券代码：603579 证券简称：荣泰健康公告编号：2025-060 债券代码：113606 债券简称：荣泰转债 上海荣泰健康科技股份有限公司 关于实施"荣泰转债"赎回暨摘牌的第四次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至2025年8月29日收市后，距离9月8日（"荣泰转债"最后交易日）仅剩6个交易日，9月8日为"荣泰转 债"最后一个交易日。 ● 最后转股日：2025年9月11日 截至2025年8月29日收市后，距离9月11日（"荣泰转债"最后转股日）仅剩9个交易日，9月11日为"荣泰 转债"最后一个转股日。 ● 本次提前赎回完成后，"荣泰转债"将自2025年9月12日起在上海证券交易所摘牌。 ● 投资者所持"荣泰转债"除在规定时限内通过二级市场继续交易或按照23.07元/股的转股价格进行转股 外，仅能选择以100元/张的票面价格加当期应计利息2.1713元/张（即合计102.1713元/张）被强制赎回。 若被强制赎回，可能面临较大投资损失。 ● 公司提醒"荣泰转债"持有人注意在限期内转 ...

Market Overview - The other home appliance sector declined by 1.39% on August 29, with Aojiahua leading the drop [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Stock Performance - Key stocks in the other home appliance sector showed the following performance: - Rongtai Health (603579) closed at 37.02, down 1.31% with a trading volume of 64,900 shares and a transaction value of 240 million yuan [1] - Ronger Health (300247) closed at 4.53, down 1.31% with a trading volume of 241,100 shares and a transaction value of 109 million yuan [1] - Aojiahua (002614) closed at 6.94, down 1.70% with a trading volume of 142,500 shares and a transaction value of 99.38 million yuan [1] Capital Flow - The other home appliance sector experienced a net outflow of 27.50 million yuan from main funds, while retail funds saw a net inflow of 6.77 million yuan [1] - Detailed capital flow for key stocks: - Aojiahua (002614) had a main fund net outflow of 5.49 million yuan and a retail net inflow of 1.31 million yuan [1] - Ronger Health (300247) had a main fund net outflow of 7.96 million yuan and a retail net inflow of 7.09 million yuan [1] - Rongtai Health (603579) had a main fund net outflow of 14.05 million yuan and a retail net inflow of 7.33 million yuan [1]

Core Points - The company is implementing the early redemption of "Rongtai Convertible Bonds" with a redemption price of 102.1713 CNY per bond [1][4] - The redemption registration date is set for September 11, 2025, with the last trading day on September 8, 2025 [1][6] - The last conversion date for the bonds is also September 11, 2025, after which the bonds will be delisted from the Shanghai Stock Exchange [1][7] Redemption Conditions - The company has triggered the conditional redemption clause due to its stock price being at least 130% of the conversion price for 15 out of 30 trading days [2][3] - The conversion price is set at 23.07 CNY per share, meaning the stock price must be at least 29.99 CNY for the redemption to occur [2][3] Interest Calculation - The accrued interest for the bonds is calculated using the formula: IA = B × i × t / 365, where B is the total face value, i is the annual coupon rate of 2.5%, and t is the number of days from the last interest payment to the redemption date [3][4] - The total accrued interest amounts to 2.1713 CNY per bond, leading to a total redemption price of 102.1713 CNY per bond [4] Tax Implications - Individual investors will be subject to a 20% tax on the interest income, resulting in a net redemption amount of 101.7370 CNY per bond after tax [4][5] - Corporate investors are exempt from income tax on the interest income, receiving the full redemption amount of 102.1713 CNY per bond [5] Redemption Process - The company will notify bondholders of the redemption details before the redemption period ends, and all unconverted bonds will be frozen after the registration date [5][6] - Redemption payments will be distributed on September 12, 2025, through the designated trading institutions [5][6]

| | | 上海荣泰健康科技股份有限公司 关于实施"荣泰转债"赎回暨摘牌的第四次提示性 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至2025年8月29日收市后，距离9月8日（"荣泰转债"最后交易日）仅剩 6个交易日，9月8日为"荣泰转债"最后一个交易日。 最后转股日：2025 年 9 月 11 日 截至2025年8月29日收市后，距离9月11日（"荣泰转债"最后转股日）仅 剩9个交易日，9月11日为"荣泰转债"最后一个转股日。 本次提前赎回完成后，"荣泰转债"将自 2025 年 9 月 12 日起在上海证 券交易所摘牌。 投资者所持"荣泰转债"除在规定时限内通过二级市场继续交易或按照 23.07 元/股的转股价格进行转股外，仅能选择以 100 元/张的票面价格加当期 应计利息 2.1713 元/张（即合计 102.1713 元/张）被强制赎回。若被强制赎回， 可能面临较大投资损失。 公司提醒"荣泰转债"持有人注意在限期内转股或卖出。 上海荣泰健康科技股份有限公司（以下简称"公司"）股票自 2025 ...

Group 1 - The core viewpoint of the report is that Rongtai Health (603579.SH) is given a "buy" rating due to strong performance indicators and growth potential [1] - Domestic online sales are expected to grow by over 30% year-on-year in the first half of 2025, with excellent performance in emerging overseas markets and cross-border e-commerce [1] - Gross margin improved in Q2 2025, supported by increased R&D investment and operational efficiency [1] - The company is diversifying its smart health business, leveraging technology for accelerated growth [1]

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：113606 | 债券简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 公司提醒"荣泰转债"持有人注意在限期内转股或卖出。 上海荣泰健康科技股份有限公司（以下简称"公司"）股票自 2025 年 7 月 29 日至 2025 年 8 月 18 日，已在连续三十个交易日内有十五个交易日的收盘价 赎回登记日：2025 年 9 月 11 日 赎回价格：102.1713 元/张 赎回款发放日：2025 年 9 月 12 日 最后交易日：2025 年 9 月 8 日 关于实施"荣泰转债"赎回暨摘牌的第三次提示性 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至2025年8月28日收市后，距离9月8日（"荣泰转债"最后交易日）仅剩 7个交易日，9月8日为"荣泰转债"最后一个交易日。 最后转股日：2025 年 9 月 11 日 截至2025年8月28日收市后，距离9月11日 ...

Group 1 - The core viewpoint of the article is the announcement of the company's half-year report for 2025, detailing the financial status and the use of raised funds from convertible bonds [5][27][59] - The company raised a total of RMB 600 million from the issuance of 6 million convertible bonds, with a net amount of RMB 593.98 million after deducting issuance costs [6][7] - As of June 30, 2025, the remaining balance of the raised funds is RMB 527.30 million, which includes RMB 79.30 million in the special account and RMB 448 million in large time deposits [7][14] Group 2 - The company has used RMB 1.93 million of the raised funds in the first half of 2025, with a total of RMB 4.23 million used in 2021, RMB 1.08 million in 2022, and RMB 4.97 million in 2024 [7][12] - The company has not used any idle raised funds to temporarily supplement working capital or for other purposes during the reporting period [13][18] - The company has established a special account for the management of raised funds, ensuring compliance with regulations and proper usage [9][10] Group 3 - The company plans to hold an investor performance briefing on September 4, 2025, to discuss the half-year results and address investor concerns [29][31] - The company’s board of directors and supervisory board have approved the half-year report and the special report on the use of raised funds [27][59] - The company has triggered the conditional redemption clause for its convertible bonds due to the stock price exceeding 130% of the conversion price for a specified period [41][43]

Group 1 - The core point of the news is that Rongtai Health experienced a decline of 5.34% in its stock price, reaching 35.29 CNY per share, with a trading volume of 264 million CNY and a turnover rate of 3.79%, resulting in a total market capitalization of 6.777 billion CNY [1] - Rongtai Health, established on November 15, 2002, and listed on January 11, 2017, is primarily engaged in the design, research and development, production, and sales of massage equipment [1] Group 2 - Among the top ten circulating shareholders of Rongtai Health, a fund under the Fortune Fund ranks as a significant shareholder, with the Fortune Emerging Industries Stock A/B (001048) newly entering the top ten in the second quarter, holding 2.5575 million shares, which accounts for 1.44% of the circulating shares [2] - The Fortune Emerging Industries Stock A/B (001048) was established on March 12, 2015, with a latest scale of 3.137 billion CNY. It has achieved a year-to-date return of 48.54%, ranking 189 out of 4222 in its category, and a one-year return of 120.88%, ranking 65 out of 3776 [2] Group 3 - The fund manager of Fortune Emerging Industries Stock A/B (001048) is Sun Quan, who has been in the position for 3 years and 183 days. The total asset scale of the fund is 7.75 billion CNY, with the best fund return during his tenure being 84.61% and the worst being 31.73% [3]

Core Insights - Rongtai Health and Aosha Intelligent have signed a strategic cooperation agreement, marking a new chapter in the integration of health technology and exoskeleton technology [1] - The partnership aims to explore the potential of "human-machine symbiosis" and accelerate the application of cutting-edge intelligent technology in the health industry [1] Company Overview - Rongtai Health has been deeply involved in the health industry for 28 years, with products sold in over 80 countries and regions, and has sold more than 3 million massage chairs [1] - Aosha Intelligent specializes in exoskeleton robotics, with a focus on transitioning technology from industrial applications to the consumer market [1] Future Plans - The two companies plan to establish deep cooperation in three core areas: technological health, industry applications, and technology research and development, aiming for complementary advantages and collaborative development [1] - Both companies express commitment to continue deepening their partnership to explore the infinite possibilities of "health + technology" [1]

Core Insights - Rongtai Health reported a revenue of 810,202,891.61 yuan for the first half of 2025, representing a year-on-year decline of 1.78% [1] - The net profit attributable to shareholders of the listed company was 85,336,914.36 yuan, showing a year-on-year decrease of 23.35% [1]